Format

Send to

Choose Destination
Drug Metab Pharmacokinet. 2007 Oct;22(5):328-35.

Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.

Author information

1
Department of Pharmacokinetics Dynamics Metabolism, Pfizer Global Research Development, Nagoya Laboratories, Pfizer Japan Inc, Aichi, Japan. kazuhide.iwasaki@pfizer.com

Abstract

Tacrolimus (FK506), an immunosuppressive drug, is co-medicated with multiple drugs under clinical conditions. Tacrolimus is highly lipophilic and is excreted from the body after receiving extensive metabolism. Due to its narrow therapeutic window following organ transplantation, tacrolimus requires therapeutic drug monitoring by an enzyme immunoassay using the monoclonal antibody raised against tacrolimus. Therefore, metabolism studies including drug-drug interaction and metabolite identification studies are essential for the efficient development and clinically optimal usage of this drug. Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily. Metabolic drug-drug interaction studies were conducted to provide information regarding the optimal usage of tacrolimus, and its metabolism was inhibited by known CYP3A inhibitors such as ketoconazole, cyclosporine A, and nifedipine. Recent reports on clinical pharmacokinetics indicate that dose levels of tacrolimus need to be adjusted in transplant patients with CYP3A5 polymorphism.

PMID:
17965516
DOI:
10.2133/dmpk.22.328
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
Loading ...
Support Center